Fosamax class action

On March 2010, the FDA began a safety review of Fosamax to determine whether or not there is an increase in the risk of bone fractures.  The agency is investigating the possible link between Fosamax and fractures that occur below the hip joint on patients who have been on bisphosphonates for several years.  The investigation is still on going but the FDA suggests that for patients who are currently on bisphosphonates should continue therapy but should make sure they talk to their healthcare providers if they develop any symptoms.

Fosamax Lawyer

Fosamax lawyer Evidence has also revealed that Fosamax can increase the risk of osteonecrosis, a serious bone disease of the jaw (ONJ). According to experts in the field, ONJ is a condition in which the bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, causing the bone to be exposed. This exposure can lead to infection, fracture, and extensive tissue death, requiring long-term antibiotic use or surgery to correct.
One study, quoted by United Press International in April 2006, found that nearly 2,500 patients taking a bisphosphonate like Fosamax, have suffered jaw-bone damage since 2001. Another 120 patients suffered incapacitating bone, muscle, or joint pain. Health experts have discovered 1,100 cases of Fosamax osteonecrosis in the past six to nine months